Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the best biotech stocks to buy. On September 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed the findings of its Phase 2 COURAGE trial, which demonstrated that semaglutide and trevogrumab together preserved lean muscle mass while treating obesity with weight loss.

According to the 26-week trial, semaglutide by itself resulted in a 33% of weight loss to come from lean mass loss. In patients treated with semaglutide, around half of the muscle mass that would have been lost was preserved when trevogrumab, an anti-GDF8/anti-myostatin antibody, was introduced.

The study’s weight-loss phase results were reported at the European Association for the Study of Diabetes meeting. In the meantime, patients will continue in a weight maintenance phase through week 52.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a prominent biopharmaceutical company that discovers, develops, and commercializes medicines for a variety of diseases, including cancer, eye disorders, and allergies.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.